Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

2.

Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Carlton AL, Illendula A, Gao Y, Llaneza DC, Boulton A, Shah A, Rajewski RA, Landen CN, Wotton D, Bushweller JH.

Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.

PMID:
29551565
3.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.

PMID:
29523763
4.

Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor.

McQueeney KE, Salamoun JM, Burnett JC, Barabutis N, Pekic P, Lewandowski SL, Llaneza DC, Cornelison R, Bai Y, Zhang ZY, Catravas JD, Landen CN, Wipf P, Lazo JS, Sharlow ER.

Oncotarget. 2017 Dec 30;9(9):8223-8240. doi: 10.18632/oncotarget.23787. eCollection 2018 Feb 2.

5.

Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.

Cornelison R, Llaneza DC, Landen CN.

Int J Mol Sci. 2017 Oct 18;18(10). pii: E2171. doi: 10.3390/ijms18102171. Review.

6.

Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Cornelison R, Dobbin ZC, Katre AA, Jeong DH, Zhang Y, Chen D, Petrova Y, Llaneza DC, Steg AD, Parsons L, Schneider DA, Landen CN.

Clin Cancer Res. 2017 Nov 1;23(21):6529-6540. doi: 10.1158/1078-0432.CCR-17-0282. Epub 2017 Aug 4.

7.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

8.

Metastatic papillary serous uterine cancer presenting as a rash.

Chang ES, Baker WD, Landen CN.

Gynecol Oncol Rep. 2016 Sep 8;18:11-3. doi: 10.1016/j.gore.2016.09.001. eCollection 2016 Nov.

9.

The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.

Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, Conner MG, Arend RC, Yoon KJ, Klug CA, Bullard DC, Kesterson RA, Oliver PG, O'Connor AK, Yoder BK, Bellis SL.

Cancer Res. 2016 Jul 1;76(13):3978-88. doi: 10.1158/0008-5472.CAN-15-2834. Epub 2016 May 23.

10.

Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting.

Fuh K, Vlad AM, Landen CN Jr.

Gynecol Oncol. 2016 Jul;142(1):9-12. doi: 10.1016/j.ygyno.2016.05.013. Epub 2016 May 27. No abstract available.

PMID:
27181388
11.

Summary of the 2015 American Association for Cancer Research (AACR) Annual Meeting.

Chien J, Landen CN.

Gynecol Oncol. 2015 Jul;138(1):7-10. No abstract available.

PMID:
26269806
12.

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.

13.

Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN.

Oncotarget. 2014 Aug 30;5(16):7065-80.

14.

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN.

Oncotarget. 2014 Sep 30;5(18):8750-64.

15.

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.

Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.

16.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
17.

Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications.

Dobbin ZC, Landen CN.

Curr Protoc Pharmacol. 2013 Dec 2;63:Unit 14.28.. doi: 10.1002/0471141755.ph1428s63.

18.

EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.

Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN Jr, Eblen ST.

Carcinogenesis. 2014 May;35(5):1100-9. doi: 10.1093/carcin/bgt489. Epub 2013 Dec 30.

19.

Ovarian cancer stem cells: are they real and why are they important?

Shah MM, Landen CN.

Gynecol Oncol. 2014 Feb;132(2):483-9. doi: 10.1016/j.ygyno.2013.12.001. Epub 2013 Dec 7. Review.

20.

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.

Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM Jr, Landen CN, Ferrone S, Buchsbaum DJ.

Gynecol Oncol. 2014 Jan;132(1):203-10. doi: 10.1016/j.ygyno.2013.10.038. Epub 2013 Nov 9.

PMID:
24216048
21.

Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.

Landen CN Jr, Lengyel E.

Gynecol Oncol. 2013 Jul;130(1):6-8. No abstract available.

PMID:
23926600
22.

Reply: To PMID 23583217.

Erickson BK, Landen CN Jr, Conner MG.

Am J Obstet Gynecol. 2013 Oct;209(4):396. doi: 10.1016/j.ajog.2013.05.016. Epub 2013 May 9. No abstract available.

PMID:
23665249
23.

The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Dobbin ZC, Landen CN.

Int J Mol Sci. 2013 Apr 15;14(4):8213-27. doi: 10.3390/ijms14048213. Review.

24.

The role of the fallopian tube in the origin of ovarian cancer.

Erickson BK, Conner MG, Landen CN Jr.

Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10. Review.

25.

ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells.

Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL.

J Ovarian Res. 2013 Apr 11;6(1):25. doi: 10.1186/1757-2215-6-25.

26.
27.

Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.

Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO.

Exp Cell Res. 2013 Mar 10;319(5):697-706. doi: 10.1016/j.yexcr.2012.12.026. Epub 2013 Jan 16.

28.

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN.

Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12.

29.

SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, Zhang R.

Mol Cancer Res. 2012 Nov;10(11):1462-72. doi: 10.1158/1541-7786.MCR-12-0335. Epub 2012 Sep 10.

30.

Management of complex pelvic masses using a multivariate index assay: a decision analysis.

Kim KH, Zsebik GN, Straughn JM Jr, Landen CN Jr.

Gynecol Oncol. 2012 Sep;126(3):364-8. doi: 10.1016/j.ygyno.2012.05.027. Epub 2012 May 30.

31.

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN.

Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2.

32.

Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.

Ziebarth AJ, Landen CN Jr, Alvarez RD.

Clin Obstet Gynecol. 2012 Mar;55(1):156-72. doi: 10.1097/GRF.0b013e31824b1699. Review.

PMID:
22343235
33.

Paraneoplastic thrombocytosis in ovarian cancer.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Lamkin, Donald [added].

34.

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

35.

Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.

Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK.

J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.

36.

Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN.

Clin Cancer Res. 2011 Sep 1;17(17):5674-85. doi: 10.1158/1078-0432.CCR-11-0432. Epub 2011 Jul 13.

37.

Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.

Frederick PJ, Ramirez PT, McQuinn L, Milam MR, Weber DM, Coleman RL, Gershenson DM, Landen CN Jr.

Int J Gynecol Cancer. 2011 Jul;21(5):831-6. doi: 10.1097/IGC.0b013e31821743f9.

PMID:
21613957
38.

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.

Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. Epub 2010 Dec 15.

39.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK.

Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1.

40.

Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.

Worley MJ Jr, Landen CN, Slomovitz BM, Malpica A, Palla SL, Ramirez PT.

Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):509-11. doi: 10.1097/PAI.0b013e3181e78fe0.

PMID:
20661130
41.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

42.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

43.

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.

J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29.

44.

Dual targeting of EphA2 and FAK in ovarian carcinoma.

Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK.

Cancer Biol Ther. 2009 Jun;8(11):1027-34. Epub 2009 Jun 24.

45.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

46.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

47.

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

48.

EphA2 overexpression promotes ovarian cancer growth.

Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK.

Cancer Biol Ther. 2008 Jul;7(7):1098-103. Epub 2008 Apr 19.

49.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028. Erratum in: Am J Obstet Gynecol. 2018 May 22;:.

50.

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.

Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK.

J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. doi: 10.1093/jnci/djn024. Epub 2008 Feb 26.

Supplemental Content

Loading ...
Support Center